Business Context and Reporting Period
This Form 8-K is a current report filed by Oncocyte Corporation (trading symbol: OCX) on November 10, 2022. The filing serves to announce the company's financial results for the three and nine months ended September 30, 2022. The detailed results are contained in a press release attached as Exhibit 99.1, which is incorporated by reference.
Key Financial Metrics
The provided text is a cover sheet and does not contain specific numerical data regarding revenue, profit, cash flow, margins, debt, or liquidity. These figures are referenced as being located in the attached press release (Exhibit 99.1), which is not included in the input text.
Material Changes
The filing text does not provide specific details on material changes versus prior periods. It only confirms that results for the three and nine months ended September 30, 2022, have been announced.
Guidance, Outlook, and Risks
The text contains no management commentary, forward-looking guidance, specific risk factors, or details on contingencies. It includes a standard disclaimer stating that the information furnished in Item 2.02 and Exhibit 99.1 is not deemed "filed" under Section 18 of the Exchange Act and shall not be incorporated by reference into other filings unless expressly stated.
Investor Verification Checklist
- Verify the specific revenue and net loss figures for the three and nine months ended September 30, 2022, by reviewing the attached press release (Exhibit 99.1).
- Confirm the company's cash position and burn rate as detailed in the full financial statements referenced in the press release.
- Review the full text of the press release for any updates on clinical trial progress or regulatory milestones, as these are not detailed in the 8-K cover sheet.
- Note that the registrant is Oncocyte Corporation, not "Insight Molecular Diagnostics Inc." as indicated in the request metadata.